IL1R1 and neoplasm: This is in line with multiple reports demonstrating that disruption of TNFα or IL-1R/IL-1β signaling by either blocking antibodies or deficient mouse models improves the anti-tumor immune response in combination with 5-FU (50, 51) or ICB (52, 53).